

Participants with Severe Adverse Events  
(Incidence  $\geq 0\%$  in One or More Treatment Groups)  
(ASaT Population)

|  | Placebo | Xanomeline Low Dose | Xanomeline High Dose |
|--|---------|---------------------|----------------------|
|  | n       | n                   | n                    |
| Participants in population                           | 86      | 84                  | 84                   |
| with one or more severe AE                           | 7       | 16                  | 8                    |
| with no severe AE                                    | 79      | 68                  | 76                   |
| cardiac disorders                                    | 3       | 0                   | 1                    |
| atrial fibrillation                                  | 0       | 0                   | 1                    |
| atrioventricular block second degree                 | 1       | 0                   | 0                    |
| myocardial infarction                                | 2       | 0                   | 0                    |
| gastrointestinal disorders                           | 0       | 0                   | 2                    |
| gastrointestinal haemorrhage                         | 0       | 0                   | 1                    |
| nausea   | 0       | 0                   | 1                    |
| general disorders and administration site conditions | 0       | 7                   | 0                    |
| application site dermatitis                          | 0       | 1                   | 0                    |
| application site erythema                            | 0       | 2                   | 0                    |
| application site irritation                          | 0       | 3                   | 0                    |
| application site pruritus                            | 0       | 1                   | 0                    |
| application site warmth                              | 0       | 1                   | 0                    |

Participants with Severe Adverse Events  
(Incidence  $\geq$  0% in One or More Treatment Groups)  
(ASaT Population)

|   | Placebo | Xanomeline Low Dose | Xanomeline High Dose |
|---|---------|---------------------|----------------------|
|   | n       | n                   | n                    |
| general disorders and administration site conditions                | 0       | 7                   | 0                    |
| sudden death  | 0       | 1                   | 0                    |
| infections and infestations   | 0       | 1                   | 0                    |
| nasopharyngitis   | 0       | 1                   | 0                    |
| injury, poisoning and procedural complications                      | 1       | 0                   | 1                    |
| hip fracture  | 1       | 0                   | 1                    |
| musculoskeletal and connective tissue disorders                     | 1       | 1                   | 0                    |
| arthritis   | 1       | 0                   | 0                    |
| muscle spasms   | 0       | 1                   | 0                    |
| neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0       | 1                   | 1                    |
| colon cancer  | 0       | 1                   | 0                    |
| prostate cancer   | 0       | 0                   | 1                    |
| nervous system disorders  | 0       | 3                   | 4                    |
| dizziness   | 0       | 0                   | 1                    |
| headache  | 0       | 1                   | 0                    |
| partial seizures with secondary generalisation                      | 0       | 0                   | 1                    |
| stupor  | 0       | 1                   | 0                    |
| syncope   | 0       | 2                   | 1                    |
| transient ischaemic attack  | 0       | 1                   | 1                    |

Participants with Severe Adverse Events  
(Incidence  $\geq$  0% in One or More Treatment Groups)  
(ASaT Population)

|  | Placebo | Xanomeline Low Dose | Xanomeline High Dose |
|--|---------|---------------------|----------------------|
|  | n       | n                   | n                    |
| psychiatric disorders                    | 1       | 1                   | 0                    |
| agitation                                | 0       | 1                   | 0                    |
| completed suicide                        | 1       | 0                   | 0                    |
| reproductive system and breast disorders | 1       | 0                   | 0                    |
| benign prostatic hyperplasia             | 1       | 0                   | 0                    |
| skin and subcutaneous tissue disorders   | 0       | 4                   | 1                    |
| blister                                  | 0       | 1                   | 0                    |
| pruritus                                 | 0       | 1                   | 0                    |
| rash                                     | 0       | 1                   | 1                    |
| skin irritation                          | 0       | 1                   | 0                    |
| This is footnote                         |         |                     |                      |

Source: [Study MK9999P001: adam-adae]